Posttranscriptional deregulation of MYC via PTEN constitutes a major alternative pathway of MYC activation in T-cell acute lymphoblastic leukemia

Blood

Volumn 117, Issue 24, 2011, Pages 6650-6659

  Bonnet, Mélanie ^a,b,c   Loosveld, Marie ^a,b,c,d   Montpellier, Bertrand ^a,b,c   Navarro, Jean Marc ^a,b,c   Quilichini, Benoit ^d   Picard, Christophe ^e,f   Cristofaro, Julie Di ^f   Bagnis, Claude ^f   Fossat, Chantal ^d   Hernandez, Lucie ^g   Mamessier, Emilie ^a,b,c   Roulland, Sandrine ^a,b,c   Morgado, Ester ^a,b,c   Formisano Tréziny, Christine ^e   Dik, Willem A ^h   Langerak, Anton W ^h   Prebet, Thomas ⁱ   Vey, Norbert ⁱ   Michel, Gérard ^g   Gabert, Jean ^e   Soulier, Jean ^g   Macintyre, Elizabeth A ^j,k   Asnafi, Vahid ^j,k   Payet Bornet, Dominique ^a,b,c   Nadel, Bertrand ^a,b,c   more..

^a CENTRE D IMMUNOLOGIE DE MARSEILLE LUMINY   (France)

^b INSERM   (France)

^c CNRS   (France)

^d TIMONE HOSPITAL   (France)

^e HÔPITAL NORD   (France)

^f ETABLISSEMENT FRANÇAIS DU SANG   (France)

^g SAINT LOUIS HOSPITAL   (France)

^h ERASMUS MEDICAL CENTER   (Netherlands)

ⁱ INSTITUT PAOLI CALMETTES   (France)

^j UNIVERSITÉ PARIS DESCARTES   (France)

^k HÔPITAL NECKER ENFANTS MALADES   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

MYC PROTEIN; NOTCH1 RECEPTOR; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; ARTICLE; CHILD; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GENE ACTIVATION; GENE EXPRESSION; GENE MUTATION; GENE SEQUENCE; HUMAN; IMMUNOBLOTTING; MAJOR CLINICAL STUDY; MALE; MOLECULAR GENETICS; ONCOGENE MYC; PRIORITY JOURNAL; T CELL LEUKEMIA; TRANSCRIPTION REGULATION;

EID: 79959248268     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-02-336842     Document Type: Article

References (50)

1. Pui CH, Evans WE. Treatment of acute lymphoblastic leukemia. N Engl J Med. 2006;354(2):166-178. (Pubitemid 43076714)
2. Van Vlierberghe P, Pieters R, Beverloo HB, Meijerink JP. Molecular-genetic insights in paediatric T-cell acute lymphoblastic leukaemia. Br J Haematol. 2008;143(2):153-168.
3. Clappier E, Cuccuini W, Kalota A, et al. The CMYB locus is involved in chromosomal translocation and genomic duplications in human T-cell acute leukemia (T-ALL), the translocation defining a new T-ALL subtype in very young children. Blood. 2007;110(4):1251-1261. (Pubitemid 47281423)
4. Ferrando AA, Neuberg DS, Staunton J, et al. Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia. Cancer Cell. 2002;1(1):75-87. (Pubitemid 41039178)
5. Asnafi V, Beldjord K, Boulanger E, et al. Analysis of TCR, pT alpha, and RAG-1 in T-acute lymphoblastic leukemias improves understanding of early human T-lymphoid lineage commitment. Blood. 2003;101(7):2693-2703. (Pubitemid 36857632)
6. Weng AP, Ferrando AA, Lee W, et al. Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science. 2004;306(5694): 269-271. (Pubitemid 39336870)
7. Thompson BJ, Buonamici S, Sulis ML, et al. The SCFFBW7 ubiquitin ligase complex as a tumor suppressor in T cell leukemia. J Exp Med. 2007; 204(8):1825-1835. (Pubitemid 47236320)
8. Palomero T, Sulis ML, Cortina M, et al. Mutational loss of PTEN induces resistance to NOTCH1 inhibition in T-cell leukemia. Nat Med. 2007;13(10): 1203-1210. (Pubitemid 47530629)
9. Weng AP, Millholland JM, Yashiro-Ohtani Y, et al. c-Myc is an important direct target of Notch1 in T-cell acute lymphoblastic leukemia/lymphoma. Genes Dev. 2006;20(15):2096-2109. (Pubitemid 44157460)
10. Palomero T, Lim WK, Odom DT, et al. NOTCH1 directly regulates c-MYC and activates a feed-forward-loop transcriptional network promoting leukemic cell growth. Proc Natl Acad Sci U S A. 2006;103(48):18261-18266. (Pubitemid 44871646)
11. Sharma VM, Calvo JA, Draheim KM, et al. Notch1 contributes to mouse T-cell leukemia by directly inducing the expression of c-myc. Mol Cell Biol. 2006;26(21):8022-8031. (Pubitemid 44631001)
12. Li X, Gounari F, Protopopov A, Khazaie K, von Boehmer H. Oncogenesis of T-ALL and non-malignant consequences of overexpressing intracellular NOTCH1. J Exp Med. 2008;205(12): 2851-2861.
13. Dang CV, O'Donnell KA, Zeller KI, Nguyen T, Osthus RC, Li F. The c-Myc target gene network. Semin Cancer Biol. 2006;16(4):253-264. (Pubitemid 44311039)
14. Albihn A, Johnsen JI, Henriksson MA. MYC in oncogenesis and as a target for cancer therapies. Adv Cancer Res. 2010;107:163-224.
15. Junttila MR, Westermarck J. Mechanisms of MYC stabilization in human malignancies. Cell Cycle. 2008;7(5):592-596. (Pubitemid 351498996)
16. Meyer N, Penn LZ. Reflecting on 25 years with MYC. Nat Rev Cancer. 2008;8(12):976-990.
17. Hemann MT, Bric A, Teruya-Feldstein J, et al. Evasion of the p53 tumour surveillance network by tumour-derived MYC mutants. Nature. 2005; 436(7052):807-811. (Pubitemid 41160633)
18. Berns A. Cancer: two in one. Nature. 2005; 436(7052):787-789. (Pubitemid 41160626)
19. Hann SR. Role of post-translational modifications in regulating c-Myc proteolysis, transcriptional activity and biological function. Semin Cancer Biol. 2006;16(4):288-302. (Pubitemid 44311043)
20. Sears RC. The life cycle of C-myc: from synthesis to degradation. Cell Cycle. 2004;3(9):1133-1137. (Pubitemid 40268631)
21. Boyer J. t(8;14) (q24;q11) Atlas Genet Cytogenet Oncol Haematol. http://AtlasGeneticsOncology.org/Anomalies/t0814ID1061.html. Accessed April 2001.
22. Eischen CM, Weber JD, Roussel MF, Sherr CJ, Cleveland JL. Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesis. Genes Dev. 1999;13(20):2658-2669. (Pubitemid 29508553)
23. Langenau DM, Traver D, Ferrando AA, et al. Myc-induced T cell leukemia in transgenic zebrafish. Science. 2003;299(5608):887-890. (Pubitemid 36182446)
24. Smith DP, Bath ML, Harris AW, Cory S. T-cell lymphomas mask slower developing B-lymphoid and myeloid tumours in transgenic mice with broad haemopoietic expression of MYC. Oncogene. 2005;24(22):3544-3553. (Pubitemid 40756224)
25. Stewart M, Cameron E, Campbell M, et al. Conditional expression and oncogenicity of c-myc linked to a CD2 gene dominant control region. Int J Cancer. 1993;53(6):1023-1030. (Pubitemid 23119555)
26. Guo W, Lasky JL, Chang CJ, et al. Multi-genetic events collaboratively contribute to Pten-null leukaemia stem-cell formation. Nature. 2008; 453(7194):529-533. (Pubitemid 351733319)
27. Guo Z, Dose M, Kovalovsky D, et al. Beta-catenin stabilization stalls the transition from double-positive to single-positive stage and predisposes thymocytes to malignant transformation. Blood. 2007; 109(12):5463-5472. (Pubitemid 46890570)
28. Wierstra I, Alves J. The c-myc promoter: still MysterY and challenge. Adv Cancer Res. 2008;99: 113-333. (Pubitemid 350137254)
29. O'Neil J, Grim J, Strack P, et al. FBW7 mutations in leukemic cells mediate NOTCH pathway activation and resistance to {gamma}-secretase inhibitors. J Exp Med. 2007;204(8):1813-1824. (Pubitemid 47236319)
30. Maser RS, Choudhury B, Campbell PJ, et al. Chromosomally unstable mouse tumours have genomic alterations similar to diverse human cancers. Nature. 2007;447(7147):966-971. (Pubitemid 46975753)
31. Asnafi V, Buzyn A, Le Noir S, et al. NOTCH1/ FBXW7 mutation identifies a large subgroup with favorable outcome in adult T-cell acute lymphoblastic leukemia (T-ALL): a Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL) study. Blood. 2009;113(17):3918-3924.
32. Beillard E, Pallisgaard N, van der Velden V, et al. Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using 'real-time' quantitative reverse-transcriptase polymerase chain reaction (RQPCR) - a Europe against cancer program. Leukemia. 2003;17(12):2474-2486.
33. Sirven A, Ravet E, Charneau P, et al. Enhanced transgene expression in cord blood CD34(+)-derived hematopoietic cells, including developing T cells and NOD/SCID mouse repopulating cells, following transduction with modified trip lentiviral vectors. Mol Ther. 2001;3(4):438-448. (Pubitemid 32509837)
34. Larson Gedman A, Chen Q, Kugel Desmoulin S, et al. The impact of NOTCH1, FBW7 and PTEN mutations on prognosis and downstream signaling in pediatric T-cell acute lymphoblastic leukemia: a report from the Children's Oncology Group. Leukemia. 2009;23(8):1417-1425.
35. Silva A, Jotta PY, Silveira AB, et al. Regulation of PTEN by CK2 and Notch1 in primary T-cell acute lymphoblastic leukemia: rationale for combined use of CK2- and gamma-secretase inhibitors. Haematologica. 2010;95(4):674-678.
36. Zuurbier L, Homminga I, Calvert V, et al. NOTCH1 and/or FBXW7 mutations predict for initial good prednisone response but not for improved outcome in pediatric T-cell acute lymphoblastic leukemia patients treated on DCOG or COALL protocols. Leukemia. 2010;24(12):2014-2022.
37. Malempati S, Tibbitts D, Cunningham M, et al. Aberrant stabilization of c-Myc protein in some lymphoblastic leukemias. Leukemia. 2006;20(9): 1572-1581. (Pubitemid 44264101)
38. Park MJ, Taki T, Oda M, et al. FBXW7 and NOTCH1 mutations in childhood T cell acute lymphoblastic leukaemia and T cell non-Hodgkin lymphoma. Br J Haematol. 2009;145(2):198-206.
39. Marculescu R, Vanura K, Le T, Simon P, Jager U, Nadel B. Distinct t(7;9)(q34;q32) breakpoints in healthy individuals and individuals with T-ALL. Nat Genet. 2003;33(3):342-344. (Pubitemid 36278849)
40. Marculescu R, Vanura K, Montpellier B, et al. Recombinase, chromosomal translocations and lymphoid neoplasia: Targeting mistakes and repair failures. DNA Repair (Amst). 2006;5(9-10):1246-1258. (Pubitemid 44291609)
41. Medyouf H, Gao X, Armstrong F, et al. Acute Tcell leukemias remain dependent on Notch signaling despite PTEN and INK4A/ARF loss. Blood. 2010;115(6):1175-1184.
42. Vivanco I, Sawyers CL. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer. 2002;2(7):489-501. (Pubitemid 37328931)
43. Gutierrez A, Sanda T, Grebliunaite R, et al. High frequency of PTEN, PI3K, and AKT abnormalities in T-cell acute lymphoblastic leukemia. Blood. 2009;114(3):647-650.
44. Soucek L, Evan GI. The ups and downs of Myc biology. Curr Opin Genet Dev. 2010;20(1):91-95.
45. Huang CY, Bredemeyer AL, Walker LM, Bassing CH, Sleckman BP. Dynamic regulation of c-Myc proto-oncogene expression during lymphocyte development revealed by a GFP-c-Myc knock-in mouse. Eur J Immunol. 2008;38(2):342-349.
46. Asano T, Yao Y, Zhu J, Li D, Abbruzzese JL, Reddy SA. The PI 3-kinase/Akt signaling pathway is activated due to aberrant Pten expression and targets transcription factors NF-kappaB and c-Myc in pancreatic cancer cells. Oncogene. 2004; 23(53):8571-8580. (Pubitemid 39576463)
47. Alimonti A, Carracedo A, Clohessy JG, et al. Subtle variations in Pten dose determine cancer susceptibility. Nat Genet. 2010;42(5):454-458.
48. Chen Z, Trotman LC, Shaffer D, et al. Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature. 2005;436(7051):725-730. (Pubitemid 41117277)
49. Silva A, Yunes JA, Cardoso BA, et al. PTEN posttranslational inactivation and hyperactivation of the PI3K/Akt pathway sustain primary T cell leukemia viability. J Clin Invest. 2008;118(11):3762-3774.
50. Palomero T, Ferrando A. Oncogenic NOTCH1 control of MYC and PI3K: challenges and opportunities for anti-NOTCH1 therapy in T-cell acute lymphoblastic leukemias and lymphomas. Clin Cancer Res. 2008;14(17):5314-5317.